Drugs / ASI-02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06938347 | Nov 2025 → Sep 2026 overdue | congenital cardiovascular shunt | Agitated Solutions, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASI-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06938347 ↗ |
| Route | Intravenous | “The intravenous bolus injected dose of ASI-02 is 9 mL of saline and 1 mL of air.” NCT06938347 ↗ |